Susquehanna International Group, LLP Pharma Cyte Biotech, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 34,481 shares of PMCB stock, worth $64,134. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,481
Previous 35,228
2.12%
Holding current value
$64,134
Previous $67,000
20.9%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PMCB
# of Institutions
27Shares Held
706KCall Options Held
9.3KPut Options Held
4.6K-
Vanguard Group Inc Valley Forge, PA192KShares$357,8390.0% of portfolio
-
Geode Capital Management, LLC Boston, MA165KShares$306,4080.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$171,2817.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$153,8720.07% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.3KShares$91,6980.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $38.6M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...